This is in accordance with current EAU and NCCN guidelines recommending BRCA1/2 testing for PCa patients with high-risk and very high-risk localized or metastatic disease or for those with positive family history [6, 7]. This evidence concerns the gene BRCA1 and metastatic neoplasm.